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BACKGROUND
Monotherapy with a P2Y12 inhibitor after a minimum period of dual antiplatelet 
therapy is an emerging approach to reduce the risk of bleeding after percutaneous 
coronary intervention (PCI).
METHODS
In a double-blind trial, we examined the effect of ticagrelor alone as compared with 
ticagrelor plus aspirin with regard to clinically relevant bleeding among patients 
who were at high risk for bleeding or an ischemic event and had undergone PCI. 
After 3 months of treatment with ticagrelor plus aspirin, patients who had not had 
a major bleeding event or ischemic event continued to take ticagrelor and were 
randomly assigned to receive aspirin or placebo for 1 year. The primary end point 
was Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding. We 
also evaluated the composite end point of death from any cause, nonfatal myocar-
dial infarction, or nonfatal stroke, using a noninferiority hypothesis with an ab-
solute margin of 1.6 percentage points.
RESULTS
We enrolled 9006 patients, and 7119 underwent randomization after 3 months. 
Between randomization and 1 year, the incidence of the primary end point was 
4.0% among patients randomly assigned to receive ticagrelor plus placebo and 
7.1% among patients assigned to receive ticagrelor plus aspirin (hazard ratio, 0.56; 
95% confidence interval [CI], 0.45 to 0.68; P<0.001). The difference in risk between 
the groups was similar for BARC type 3 or 5 bleeding (incidence, 1.0% among 
patients receiving ticagrelor plus placebo and 2.0% among patients receiving tica-
grelor plus aspirin; hazard ratio, 0.49; 95% CI, 0.33 to 0.74). The incidence of death 
from any cause, nonfatal myocardial infarction, or nonfatal stroke was 3.9% in 
both groups (difference, −0.06 percentage points; 95% CI, −0.97 to 0.84; hazard 
ratio, 0.99; 95% CI, 0.78 to 1.25; P<0.001 for noninferiority).
CONCLUSIONS
Among high-risk patients who underwent PCI and completed 3 months of dual 
antiplatelet therapy, ticagrelor monotherapy was associated with a lower incidence 
of clinically relevant bleeding than ticagrelor plus aspirin, with no higher risk of 
death, myocardial infarction, or stroke. (Funded by AstraZeneca; TWILIGHT 
ClinicalTrials.gov number, NCT02270242.)
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Among patients who have an acute coronary syndrome or who have under-gone percutaneous coronary intervention 
(PCI), the risk of thrombotic events is lower with 
dual antiplatelet therapy with aspirin and a P2Y12 
receptor inhibitor than with aspirin alone.1 Even 
with dual antiplatelet therapy, the risk of adverse 
events remains unacceptably high among pa-
tients with enhanced thrombotic risk due to 
clinical factors (e.g., diabetes mellitus) or angio-
graphic factors (e.g., complex coronary artery 
disease).2-5 The use of more potent P2Y12 inhibi-
tors or extension of the duration of dual anti-
platelet therapy lowers residual ischemic risk 
among such patients but increases bleeding.6-9 
Although previously considered relatively benign, 
post-PCI bleeding has been shown to be associ-
ated with a substantial and durable risk of death, 
approximating or even exceeding that associated 
with myocardial infarction.2,10,11
Addressing the clinical imperatives of lower-
ing the risk of bleeding while preserving ische-
mic benefit requires therapeutic strategies that 
decouple thrombotic risk from hemorrhagic risk. 
One approach involves shortening the duration 
of dual antiplatelet therapy through early with-
drawal of P2Y12 inhibition.
12 Although several 
studies have shown the feasibility of this ap-
proach, they generally have enrolled predomi-
nantly low-risk patients and were underpowered 
for ischemic events.13-15 Reducing the duration of 
aspirin therapy may allow for more prolonged 
use of potent P2Y12 inhibitors while avoiding 
aspirin-related bleeding risk, particularly with 
respect to gastrointestinal toxicity.16 We designed 
the Ticagrelor with Aspirin or Alone in High-Risk 
Patients after Coronary Intervention (TWILIGHT) 
trial to test the hypothesis that in patients un-
dergoing PCI who are at high risk for ischemic 
or hemorrhagic complications and who have 
completed a 3-month course of dual antiplatelet 
therapy with ticagrelor plus aspirin, continued 
treatment with ticagrelor monotherapy would be 
superior to ticagrelor plus aspirin with respect to 
clinically relevant bleeding and would not lead 
to ischemic harm.
Me thods
Trial Design and Oversight
We conducted this randomized, placebo-controlled 
trial in 187 sites across 11 countries. The trial 
rationale and design have been described previ-
ously.17 The Icahn School of Medicine at Mount 
Sinai designed and sponsored the trial, which 
was supported by an investigator-initiated grant 
from AstraZeneca. The executive and steering 
committees were responsible for trial conduct, 
the integrity of the data analysis, and the report-
ing of results. National regulatory agencies and 
institutional review boards or ethics committees 
of participating centers approved the trial proto-
col, which is available with the full text of this 
article at NEJM.org. An independent data and 
safety monitoring board provided external over-
sight to ensure the safety of the trial partici-
pants. All the authors vouch for the adherence of 
the trial to the protocol, and the first, second, 
and last authors vouch for the accuracy and com-
pleteness of the data. The committee members 
and participating investigators are listed in Table 
S1 in the Supplementary Appendix, available at 
NEJM.org. AstraZeneca provided financial sup-
port and supplied ticagrelor for the trial but had 
no role in the design, collection, analysis, or 
interpretation of the data, in the preparation of 
the manuscript, or in the decision to submit the 
manuscript for publication.
Trial Population
Patients who underwent successful PCI with at 
least one locally approved drug-eluting stent and 
whom the treating clinician intended to dis-
charge with a regimen of ticagrelor plus aspirin 
were eligible to participate. Patients also had to 
have at least one additional clinical feature and 
one angiographic feature associated with a high 
risk of ischemic or bleeding events.2-5,17 The 
clinical criteria for high risk were an age of at 
least 65 years, female sex, troponin-positive acute 
coronary syndrome, established vascular disease, 
diabetes mellitus that was being treated with 
medication, and chronic kidney disease. Angio-
graphic criteria included multivessel coronary 
artery disease, a total stent length of more than 
30 mm, a thrombotic target lesion, a bifurcation 
lesion treated with two stents, an obstructive left 
main or proximal left anterior descending le-
sion, and a calcified target lesion treated with 
atherectomy. Key exclusion criteria included pre-
sentation with ST-segment elevation myocardial 
infarction, cardiogenic shock, ongoing long-term 
treatment with oral anticoagulants, or contrain-
dication to aspirin or ticagrelor. (Tables S2 and 
S3 show all the criteria and their relation to 
bleeding and ischemic risks.)
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on October 7, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 3
Ticagrelor with or without Aspirin after PCI
Trial Regimen
All enrolled patients received open-label ticagrel-
or (90 mg twice daily) and enteric-coated aspirin 
(81 to 100 mg daily) after the index PCI. At 3 
months after hospital discharge, patients who 
had not had a major bleeding event (see below) 
or an ischemic event (stroke, myocardial infarc-
tion, or coronary revascularization) were eligible 
to be randomly assigned in a 1:1 ratio in a 
double-blind fashion to receive aspirin or match-
ing placebo for an additional 12 months along 
with continuation of open-label ticagrelor treat-
ment. For the determination of eligibility for 
randomization, we defined a major bleeding 
event as Bleeding Academic Research Consor-
tium (BARC) type 3b or higher. BARC bleeding 
types range from 0 (no bleeding) to 5 (fatal 
bleeding); type 3b indicates overt bleeding lead-
ing to a decrease in hemoglobin level of at least 
5 mg per deciliter, cardiac tamponade, surgical 
intervention, or intravenous treatment with vaso-
active drugs. Nonadherence to treatment with 
ticagrelor or aspirin rendered patients ineligible 
for randomization. A 3-month course of dual 
antiplatelet therapy before randomization was 
considered sufficient on the basis of trials that 
have suggested equipoise for such a duration.13,18
Randomization was performed with a secure 
Web-based system; an independent statistician 
who was not involved with the trial generated 
the randomization sequence, which was strati-
fied according to site with randomly varying 
block sizes of 4, 6, and 8. Follow-up was per-
formed by telephone at 1 month after random-
ization and in person at 6 and 12 months after 
randomization. Adherence was assessed with 
manual pill counts, and nonadherence was clas-
sified according to the underlying reason, as de-
scribed previously.19 After 12 months of protocol-
mandated therapy, patients were switched to a 
standard-of-care antiplatelet regimen at the dis-
cretion of their treating physician, followed by 
final telephone follow-up 3 months later.
End Points
The primary end point was the first occurrence 
of BARC type 2, 3, or 5 bleeding between ran-
domization and 1 year in a time-to-event analy-
sis. The key secondary end point was the first 
occurrence of death from any cause, nonfatal 
myocardial infarction, or nonfatal stroke in a 
time-to-event analysis. Secondary bleeding end 
points included BARC type 3 or 5 bleeding20; 
Thrombolysis in Myocardial Infarction (TIMI) 
major or minor bleeding21; Global Utilization of 
Streptokinase and Tissue Plasminogen Activator 
for Occluded Coronary Arteries (GUSTO) moder-
ate, severe, or life-threatening bleeding22; or 
major bleeding as defined by the International 
Society on Thrombosis or Haemostasis (ISTH).23 
Other secondary end points included death from 
cardiovascular causes, myocardial infarction, 
ischemic stroke, and definite or probable stent 
thrombosis. Myocardial infarction was defined 
according to the third universal definition,24 and 
revascularization and stent thrombosis were clas-
sified according to the Academic Research Con-
sortium.25 Table S4 lists the primary and all 
secondary end points and their associated defi-
nitions. All clinical events were adjudicated by 
an external independent committee, the mem-
bers of which were unaware of the treatment-
group assignments.
Statistical Analysis
The sample-size and power calculation was based 
on a superiority assumption for the primary end 
point of BARC type 2, 3, or 5 bleeding. Assum-
ing a bleeding incidence of 4.5% at 1 year with 
ticagrelor plus aspirin, we chose a sample size of 
8200, which provided 80% power to detect a 
28% lower incidence in the ticagrelor-plus-placebo 
group with a type I error rate of 0.05. The key 
secondary end point (composite of death from 
any cause, nonfatal myocardial infarction, or non-
fatal stroke) was evaluated with the use of a 
prespecified noninferiority hypothesis. Under the 
assumption of an incidence of 8.0% at 1 year in 
the ticagrelor-plus-aspirin group, a sample size 
of 8200 provided 80% power to rule out an ab-
solute difference in risk of 1.6 percentage points, 
with a one-sided type I error rate of 0.025. This 
margin is consistent with those in other trials 
that have evaluated pharmacologic and device-
based interventions within a noninferiority 
framework.13,26
The cumulative incidence of the primary and 
secondary end points was estimated by the 
Kaplan–Meier method. Data from patients who 
had not had a primary end-point event between 
randomization and 1 year were censored at the 
time of death, the time of last known contact, or 
365 days, whichever came first. Hazard ratios 
and 95% confidence intervals were generated 
with Cox proportional-hazards models. Absolute 
differences and 95% confidence intervals for 
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primary and key secondary end points at 1 year 
were calculated with Kaplan–Meier estimates 
and Greenwood standard errors.27 Primary analy-
ses of bleeding and ischemic end points were 
performed in the intention-to-treat and per-proto-
col populations, respectively. Patients who under-
went randomization and did not fulfill enroll-
ment criteria, were not eligible for randomization, 
or never received protocol-mandated therapy were 
excluded from the per-protocol analysis.
R esult s
Patient Characteristics
From July 2015 through December 2017, a total 
of 9006 patients were enrolled after PCI, and 
7119 were randomly assigned 3 months later to 
receive ticagrelor plus placebo or ticagrelor plus 
aspirin (intention-to-treat population). The last 
patient underwent randomization in April 2018, 
and the database was locked in July 2019. Details 
regarding the reasons for 1887 enrolled patients 
not undergoing randomization, the baseline clin-
ical and procedural characteristics among patients 
who did and those who did not undergo ran-
domization, and adverse events among patients 
who did not undergo randomization are provided 
in Tables S5 through S9.
Ascertainment of the primary end point was 
complete in 98.4% of the patients who under-
went randomization, and data on vital status 
were obtained in 99.7% (Fig. 1). Demographic, 
clinical, and procedural characteristics were well 
balanced between the treatment groups; the mean 
age was 65 years, 23.8% of the patients were 
female, 36.8% had diabetes mellitus, and 64.8% 
underwent PCI for an acute coronary syndrome 
indication (29.8% with non–ST-segment elevation 
myocardial infarction) (Table 1 and Table S10). 
Adherence to ticagrelor treatment 1 year after 
randomization was similar in the ticagrelor-plus-
placebo group and the ticagrelor-plus-aspirin 
group (87.1% and 85.9%, respectively) (Fig. S1).19
Bleeding
Table 2 shows the incidences of primary (BARC) 
and secondary (TIMI, GUSTO, and ISTH) bleed-
ing end points, and Figure 2 shows the Kaplan–
Meier curves for the primary end point. The 
primary end point occurred in 141 patients 
(4.0%) who received ticagrelor plus placebo, as 
compared with 250 patients (7.1%) who received 
ticagrelor plus aspirin (hazard ratio, 0.56; 95% 
confidence interval [CI], 0.45 to 0.68; P<0.001), 
for a difference in risk of −3.08 percentage 
points (95% CI, −4.15 to −2.01). The incidence of 
BARC type 3 or 5 bleeding was 1.0% in the 
group that received ticagrelor plus placebo and 
2.0% in the group that received ticagrelor plus 
aspirin (hazard ratio, 0.49; 95% CI, 0.33 to 0.74). 
The treatment effect for the primary end point 
was consistent across predefined subgroups 
(Fig. S2).
Ischemic Events
Ischemic events were analyzed in the per-proto-
col population, which included the 7039 patients 
who underwent randomization and had no major 
deviations from the protocol (3524 who received 
ticagrelor plus placebo and 3515 who received 
ticagrelor plus aspirin). The key secondary com-
posite end point of death from any cause, non-
fatal myocardial infarction, or nonfatal stroke 
occurred in 135 patients (3.9%) who received tica-
grelor plus placebo and in 137 patients (3.9%) 
who received ticagrelor plus aspirin (hazard ratio, 
0.99; 95% CI, 0.78 to 1.25), for a difference in 
risk of −0.06 percentage points (95% CI, −0.97 
to 0.84) (Fig. 3). The incidence of death from any 
cause was similar in group that received ticagrel-
or plus placebo and the group that received tica-
grelor plus aspirin (1.0% and 1.3%, respectively), 
as were the incidences of myocardial infarction 
(2.7% in both groups) and definite or probable 
stent thrombosis (0.4% and 0.6%) (Table 2). 
There were 16 instances of ischemic stroke in 
the group that received ticagrelor plus placebo 
and 8 instances of ischemic stroke in the group 
that received ticagrelor plus aspirin (0.5% and 
0.2% of patients, respectively). The effect of tica-
grelor monotherapy on the key secondary end 
point was consistent across predefined subgroups 
(Fig. S3).
Additional Analyses
Landmark analyses of the period from 15 to 18 
months after PCI showed similar incidences of 
BARC type 2, 3, or 5 bleeding in the group that 
received ticagrelor plus placebo and the group 
that received ticagrelor plus aspirin (0.7% and 
0.5%, respectively; hazard ratio, 1.24; 95% CI, 
0.64 to 2.40); the incidence of death, myocardial 
infarction, or stroke was also similar in the two 
groups (0.9% and 1.1%; hazard ratio, 0.84; 95% 
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CI, 0.51 to 1.40). Sensitivity analyses conducted 
with an imputation-based approach to account 
for the 112 patients who were lost to clinical 
follow-up yielded similar effects for the primary 
and key secondary end points.28 (Details of these 
analyses are provided in Tables S11 and S12 and 
Fig. S4.)
Discussion
Our trial was designed to examine the effect of 
withdrawing treatment with aspirin while con-
tinuing treatment with ticagrelor alone after 
3 months of dual antiplatelet therapy in patients 
who received drug-eluting stents and were at high 
risk for bleeding or ischemic events. Ticagrelor 
monotherapy was associated with a 44% lower 
risk of BARC type 2, 3, or 5 bleeding over 1 year 
than ticagrelor plus aspirin (absolute difference 
in risk, 3.1 percentage points). The bleeding-
related benefits of ticagrelor monotherapy ex-
tended to more severe BARC type 3 or 5 bleeds 
and persisted when alternative bleeding scales 
were considered. In this trial, there was no evi-
dence of a higher risk of death, myocardial in-
farction, or stroke among patients who received 
ticagrelor monotherapy than among those who 
received ticagrelor plus aspirin. The treatment 
effect with respect to both bleeding and ische-
mic end points was consistent across subgroups. 
In aggregate, these results show that a transition 
to an antiplatelet strategy of treatment with tica-
grelor alone after a 3-month course of dual anti-
platelet therapy in high-risk patients who had 
undergone PCI provided a clinical benefit of less 
bleeding without ischemic harm.
Figure 1. Enrollment, Randomization, and Follow-up.
Patients could have been excluded from randomization for more than one type of adverse event. BARC denotes 
Bleeding Academic Research Consortium, and DAPT dual antiplatelet therapy.
7119 Underwent randomization
9006 Patients were enrolled
1887 Were excluded from randomization
106 Were lost to follow-up
243 Had adverse events
111 Had myocardial infarction, stroke, or death
134 Had any revascularization
52 Had BARC type 3b or higher bleeding event
1148 Were not adherent to DAPT
267 Withdrew consent or declined to participate
123 Had other reasons
3555 Received ticagrelor plus placebo 3564 Received ticagrelor plus aspirin
18 Withdrew consent
41 Were lost to follow-up
25 Withdrew consent
27 Were lost to follow-up
1 Was withdrawn by physician
3496 (98.3%) Completed follow-up
at mo 15 (including 34 who died)
3511 (98.5%) Completed follow-up
at mo 15 (including 48 who died)
3546 (99.7%) Had vital status
available at mo 15
3554 (99.7%) Had vital status
available at mo 15
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Two previous studies showed that among pa-
tients who had undergone PCI and were at rela-
tively low risk for ischemic events, clopidogrel 
monotherapy after 1 to 3 months of dual anti-
platelet therapy was associated with a signifi-
cantly lower incidence of bleeding than clopido-
grel plus aspirin, without an apparent difference 
in ischemic risk.29,30 The modest size of those 
studies, as well as the low-risk nature of the 
patient population, precluded conclusive infer-
ence regarding the effect of clopidogrel mono-
therapy on ischemic end points. Distinct from 
these trials, we enrolled a larger population of 
patients who more commonly had both clinical 
and angiographic high-risk criteria and were 
treated with a more potent P2Y12 inhibitor, tica-
grelor.
In contrast to our findings, the findings of the 
GLOBAL LEADERS trial showed that 1 month of 
dual antiplatelet therapy followed by ticagrelor 
monotherapy for an additional 23 months was 
not associated with a lower incidence of bleeding 
Characteristic
Ticagrelor plus Placebo 
(N = 3555)
Ticagrelor plus Aspirin 
(N = 3564)
Age — yr 65.2±10.3 65.1±10.4
Female sex — no. (%) 846 (23.8) 852 (23.9)
Nonwhite race — no. (%)† 1110 (31.2) 1086 (30.5)
Body-mass index‡ 28.6±5.5 28.5±5.6
Enrolling region — no. (%)
North America 1484 (41.7) 1488 (41.8)
Europe 1251 (35.2) 1258 (35.3)
Asia 820 (23.1) 818 (23.0)
Diabetes mellitus — no. (%) 1319 (37.1) 1301 (36.5)
Diabetes treated with insulin — no. (%) 335 (9.4) 374 (10.5)
Chronic kidney disease — no./total no. (%)§ 572/3410 (16.8) 573/3425 (16.7)
Anemia — no./total no. (%) 675/3405 (19.8) 654/3423 (19.1)
Current smoker — no./total no. (%) 726/3553 (20.4) 822/3562 (23.1)
Hypercholesterolemia — no. (%) 2157 (60.7) 2146 (60.2)
Hypertension — no./total no. (%) 2580/3555 (72.6) 2574/3563 (72.2)
Peripheral arterial disease — no. (%) 245 (6.9) 244 (6.8)
Previous myocardial infarction — no. (%) 1020 (28.7) 1020 (28.6)
Previous PCI — no. (%) 1502 (42.3) 1496 (42.0)
Previous CABG — no./total no. (%) 362/3554 (10.2) 348/3564 (9.8)
Multivessel coronary artery disease — no. (%) 2272 (63.9) 2194 (61.6)
Previous major bleeding event — no. (%) 31 (0.9) 32 (0.9)
Indication for PCI — no./total no. (%)
Asymptomatic 234/3554 (6.6) 223/3563 (6.3)
Stable angina 1047/3554 (29.5) 999/3563 (28.0)
Unstable angina 1249/3554 (35.1) 1245/3563 (34.9)
NSTEMI 1024/3554 (28.8) 1096/3563 (30.8)
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. CABG denotes coronary artery 
bypass graft, NSTEMI non–ST-segment elevation myocardial infarction, and PCI percutaneous coronary intervention.
†  Race was reported by the patient.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
§  Chronic kidney disease was defined as an estimated glomerular filtration rate of less than 60 ml per minute per 1.73 m2 
of body-surface area.
Table 1. Baseline Characteristics of the Patients Who Underwent Randomization.*
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than a conventional antiplatelet strategy.31 These 
results may be attributable to differences in trial 
design (double-blind vs. open-label), patient case 
mix (high-risk patients vs. all comers), duration 
of therapy after randomization (12 months vs. 
23 months), comparator regimens (ticagrelor plus 
aspirin vs. dual antiplatelet therapy followed by 
aspirin), bleeding ascertainment (adjudicated vs. 
site-reported), or protocol adherence. Conse-
quently, any putative bleeding-related advantage 
associated with the withdrawal of aspirin therapy 
may have been attenuated in GLOBAL LEADERS. 
For instance, ticagrelor monotherapy was associ-
ated with a nonsignificant 14% lower incidence of 
BARC type 3 or 5 bleeding at 1 year in GLOBAL 
LEADERS, whereas a 51% lower incidence was 
observed in our trial.
To be included in our trial, patients had to 
have clinical and angiographic factors associated 
with a high risk of either bleeding or ischemic 
events after PCI, design features that reflect the 
primary and key secondary end points of the 
trial. With respect to bleeding, patients at high 
risk are most likely to have a benefit from re-
duced exposure to antiplatelet therapy. With regard 
to ischemic events, we enrolled patients with a 
high risk of such events to identify signals of harm 
after withdrawal of aspirin therapy. Although 
Variable
Ticagrelor plus 
Placebo 
(N = 3555)
Ticagrelor plus 
Aspirin 
(N = 3564)
Hazard Ratio 
(95% CI)† P Value
no. of patients (%)‡
Bleeding end points
Primary end point: BARC type 2, 3, or 5§ 141 (4.0) 250 (7.1) 0.56 (0.45–0.68) <0.001¶
BARC type 3 or 5§ 34 (1.0) 69 (2.0) 0.49 (0.33–0.74)
TIMI minor or major 141 (4.0) 250 (7.1) 0.56 (0.45–0.68)
GUSTO moderate or severe 26 (0.7) 49 (1.4) 0.53 (0.33–0.85)
ISTH major 39 (1.1) 72 (2.1) 0.54 (0.37–0.80)
Ischemic end points
Death from any cause, nonfatal myocardial 
infarction, or nonfatal stroke
135 (3.9) 137 (3.9) 0.99 (0.78–1.25) <0.001‖
Death from cardiovascular causes, nonfatal 
myocardial infarction, or nonfatal  
ischemic stroke
126 (3.6) 130 (3.7) 0.97 (0.76–1.24)
Death from any cause 34 (1.0) 45 (1.3) 0.75 (0.48–1.18)
Death from cardiovascular causes 26 (0.8) 37 (1.1) 0.70 (0.43–1.16)
Myocardial infarction 95 (2.7) 95 (2.7) 1.00 (0.75–1.33)
Ischemic stroke 16 (0.5) 8 (0.2) 2.00 (0.86–4.67)
Stent thrombosis, definite or probable 14 (0.4) 19 (0.6) 0.74 (0.37–1.47)
*  Bleeding end points were evaluated in the intention-to-treat population (the 7119 patients who underwent randomization), 
and ischemic end points were evaluated in the per-protocol population (the 7039 patients who underwent randomiza-
tion and had no major deviations from the protocol [3524 who received ticagrelor plus placebo and 3515 who received 
ticagrelor plus aspirin]). All primary and secondary end points and their associated definitions are listed in Table S4. 
GUSTO denotes Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries, 
ISTH International Society on Thrombosis and Hemostasis, and TIMI Thrombolysis in Myocardial Infarction.
†  The 95% confidence intervals for secondary end points have not been adjusted for multiplicity, and therefore inferences 
drawn from these intervals may not be reproducible.
‡  Event percentages are Kaplan–Meier estimates of the incidence of the end point at 12 months after randomization.
§  Bleeding Academic Research Consortium (BARC) types range from 0 (no bleeding) to 5 (fatal bleeding).
¶  The difference in the risk of the primary end point of BARC 2, 3, or 5 bleeding was −3.08 percentage points (95% CI, 
−4.15 to −2.01).
‖  The difference in the risk of the key secondary end point of death from any cause, nonfatal myocardial infarction, or 
nonfatal stroke was −0.06 percentage points (95% CI, −0.97 to 0.84). For the key secondary end point, the upper limit 
of the 95% confidence interval for the difference indicated noninferiority (P<0.001).
Table 2. Bleeding and Ischemic Events 1 Year after Randomization.*
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most of the prespecified criteria are associated 
with excess thrombosis (e.g., diabetes mellitus), 
others are linked to both types of events (e.g., 
renal impairment). Moreover, only patients whom 
a clinician had already decided to treat with as-
pirin and ticagrelor were eligible for enrollment, 
which resulted in a trial population with a level 
of ischemic and bleeding risk that reflects the 
overall trial design and clinical preferences for 
ticagrelor use.
Major adverse events occurring early after PCI 
and nonadherence to dual antiplatelet therapy 
precluded randomization at 90 days, criteria that 
led to the population of patients who underwent 
randomization having a clinical and angiographic 
profile distinct from that of the initially enrolled 
participants. Nonetheless, several high-risk char-
acteristics (e.g., diabetes mellitus and long stent 
length) remained prevalent among the patients 
who underwent randomization. Moreover, the in-
cidences of bleeding and ischemic events at 1 year 
in these patients were similar to or higher than 
those reported in trials in which all events from 
PCI onward were considered, thereby substantiat-
ing the high-risk nature of our trial population.29-31
Although guidelines recommend ticagrelor in 
the context of acute coronary syndrome alone, 
33% of the trial participants were in stable con-
dition at the time of enrollment.1 Potential rea-
sons for the inclusion of such patients by trial 
investigators may have included a perceived lack 
of benefit with clopidogrel or clinical equipoise 
with regard to P2Y12 inhibitor choice in high-risk 
patients who are stable after PCI. Corroborating 
such tendencies, findings from usual-care regis-
tries show that in current practice, more than 
10% of patients who have undergone PCI and are 
treated with ticagrelor initially present with a 
non–acute coronary syndrome indication.32,33 From 
a clinical standpoint, our results suggest that 
ticagrelor monotherapy may be a suitable anti-
platelet strategy to lower the risk of bleeding 
while simultaneously preserving ischemic bene-
fit in patients who have undergone PCI and are 
characterized by a minimum threshold of risk. 
These effects appear consistent in patients whose 
condition is either stable or acute. Whether the 
findings would be similar in a lower-risk popu-
lation or if a different antithrombotic regimen 
were used remains unknown.
The limitations of our trial include the lack of 
power to detect differences in the risk of impor-
tant yet rare clinical events, such as stent throm-
bosis and stroke. Although ischemic strokes 
were more common among patients who re-
ceived placebo than among those who continued 
to receive aspirin, only 24 such events occurred 
Figure 2. Kaplan–Meier Estimates of the Incidence of BARC Type 2, 3,  
or 5 Bleeding 1 Year after Randomization (Intention-to-Treat Population).
The hazard ratio shown is for ticagrelor plus placebo versus ticagrelor plus 
aspirin. Bleeding Academic Research Consortium (BARC) types range from 
0 (no bleeding) to 5 (fatal bleeding). The inset shows the same data on an 
expanded y axis. CI denotes confidence interval.
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Figure 3. Kaplan–Meier Estimates of the Incidence of Death from Any Cause, 
Nonfatal Myocardial Infarction, or Nonfatal Stroke 1 Year after Randomization 
(Per-Protocol Population).
The per-protocol population included patients who underwent randomiza-
tion and had no major deviations from the protocol. The hazard ratio shown 
is for ticagrelor plus placebo versus ticagrelor plus aspirin. The inset shows 
the same data on an expanded y axis.
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during the trial, thereby precluding conclusive 
inference for this end point. Other studies have 
shown that P2Y12 inhibitor monotherapy is not 
associated with a higher risk of cerebrovascular 
events than dual antiplatelet therapy.29,30,34 Re-
sults from this trial may not be generalizable to 
all patients who have undergone PCI, given the 
requirement in our trial for both high-risk (clini-
cal and angiographic) features and a willingness 
to be treated with ticagrelor. In addition, the 
observed treatment effects do not apply to all 
enrolled participants but rather to those patients 
who were able to take 3 months of dual anti-
platelet therapy without any major adverse events. 
Our primary end point included bleeding events 
of varying severity, which may have altered the 
risk–benefit calculation for considering ticagrel-
or monotherapy. A lower-than-expected incidence 
of the composite end point of death, myocardial 
infarction, or stroke may have biased our results 
for this key secondary end point toward the null.
Our trial showed that in high-risk patients 
who had undergone PCI and were treated with 
ticagrelor and aspirin for 3 months, an anti-
platelet strategy of continuing ticagrelor alone 
resulted in substantially less bleeding than tica-
grelor plus aspirin, without leading to ischemic 
harm over a period of 1 year.
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